Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Number of holders
-
244
-
Total 13F shares, excl. options
-
35,534,767
-
Shares change
-
+4,003,036
-
Total reported value, excl. options
-
$1,506,022,854
-
Value change
-
+$153,360,658
-
Put/Call ratio
-
73%
-
Number of buys
-
137
-
Number of sells
-
95
-
Price
-
$42.41
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q1 2020
As of 31 Mar 2020 CRISPR Therapeutics AG - Common Stock (CRSP) had 244 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 35,534,767 shares of stock of the company.
Largest 10 holders included ARK Investment Management LLC, Versant Venture Management, LLC, Nikko Asset Management Americas, Inc., NEA Management Company, LLC, FEDERATED HERMES, INC., WADDELL & REED FINANCIAL INC, PRICE T ROWE ASSOCIATES INC /MD/, FMR LLC, CREDIT SUISSE AG/, and MORGAN STANLEY.
This table shows 244 institutional shareholders of the security as of 31 Mar 2020.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.